Revenue
No reported data
Pharvaris N.V. (PHVS)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Research & development | €124.5M | €98.6M | €65.6M | €57.4M | €35.8M | €19.5M | €5.7M | €3.6M |
| Operating expenses | €169.8M | €145.7M | €96.9M | €86.7M | €54.1M | €25.0M | €8.0M | €4.3M |
| Operating income | −€173.7M | −€132.4M | −€99.8M | −€75.7M | −€42.7M | −€26.1M | −€8.0M | −€4.3M |
| Net income | −€175.7M | −€134.2M | −€100.9M | −€76.3M | −€42.7M | −€26.0M | −€8.0M | −€4.3M |
| Basic EPSper diluted share | -€2.97 | -€2.48 | -€2.63 | -€2.27 | -€1.40 | -€5.36 | -€1.66 | -€0.89 |
| Diluted EPSper diluted share | -€2.97 | -€2.48 | -€2.63 | -€2.27 | -€1.40 | -€5.36 | -€1.66 | -€0.89 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | Schikan Johannes Gerardus Christiaan PetrusDirector | SellCommon Stock | 2.4K | $35.10 | $84.2K | 352.8K |
| Jun 26, 2026Form 4 · 10b5-1 | Lu PengChief Medical Officer | SellCommon Stock | 14.7K | $34.00 | $499.8K | 65.6K |
| Jun 25, 2026Form 4 · 10b5-1 | Lesage AnneChief Early Development | SellCommon Stock · indirect | 2.3K | $35.12 | $80.8K | 131.7K |
| Jun 25, 2026Form 4 · 10b5-1 | Lesage AnneChief Early Development | SellCommon Stock | 2.3K | $35.12 | $80.8K | 56.5K |
| Jun 25, 2026Form 4 · 10b5-1 | Lu PengChief Medical Officer | SellCommon Stock | 3.4K | $35.09 | $119.3K | 65.6K |